TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer
Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy. The study, Tumor MicroRNA Biomarkers Associated with De Novo Chemoresistance in Small Cell Lung Cancer, will be presented today in San Diego at a joint conference of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).
This breakthrough is critical since patients with small-cell lung cancer (SCLC) often do not get a second chance at therapies to combat this aggressive type of cancer.
"For patients with small cell lung cancer, there are really only about two chemotherapy options. We need to be more precise with our treatments and identify who is going to be resistant up front in order to design better clinical trials that will identify effective therapies for these at-risk patients," said Dr. Glen J. Weiss, director of Thoracic Oncology at TCRS, who presented the findings at AACR-IASLC's Joint Conference on Molecular Origins of Lung Cancer.
TCRS is a partnership between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare that enables laboratory discoveries to be quickly turned into targeted therapies that can be tested with patients at the Virginia G. Piper Cancer Center in Scottsdale.
Of the nearly 32,000 new cases of SCLC diagnosed in the U.S. every year, between 15 and 30 percent will be chemoresistant to first-line therapy, or about 6,500 SCLC patients annually. SCLC tends to spread much more quickly than non-small cell lung cancer. There are three types of SCLC: small cell carcinoma (oat cell cancer), mixed small cell/large cell carcinoma, and combined small cell carcinoma.
The study led by Dr. Weiss proposed to look at how to best identify those SCLC patients who would be chemoresistant. By profiling tumors, he and a team of TGen researchers identified at least three tumor microRNAs that appear to predict small cell lung cancer patients who will prove resistant to first-line chemotherapy. In addition to researchers at TGen, Dr. Weiss was assisted by scientists at the Scottsdale Clinical Research Institute and the Van Andel Research Institute.
MicroRNAs are small molecules that regulate gene expression in the process of making proteins as well as directing the structure and function of cells. This regulation usually prevents cancer and other diseases.
Weiss and colleagues evaluated 34 patients at with varying stages of SCLC. The median age of the patients was 69.1 years, and half were men. All 34 received systemic chemotherapy. There were two complete responses and 13 partial responses. Two patients had stable disease and four had progressive disease.
Three microRNAs biomarkers were identified as being closely linked with chemoresistance: miR-92a-2*, miR-147, and miR-574-5p. Although 47 percent of the patients presented with hypertension and 32 percent presented with emphysema or chronic obstructive pulmonary disease, neither of these co-morbidities were linked with chemoresistance.
These findings should help clinicians design better drug trials.
- TGen and Scottsdale Healthcare researchers discover microRNA role in brain metastasisFri, 1 Apr 2011, 12:13:03 EDT
- TGen Clinical Research Services at Scottsdale Healthcare is first to test new drug by Italian firmTue, 8 Dec 2009, 16:42:40 EST
- Results from TH-302 clinical trials presented at international lung cancer meetingThu, 6 Aug 2009, 17:30:56 EDT
- First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conferenceWed, 6 Jul 2011, 3:35:20 EDT
- New international study targets rare cancer bringing hope for advanced thymic cancer patientsTue, 8 Dec 2009, 16:42:41 EST
- Small-cell lung cancer breakthrough: MicroRNAs key to identifying patients resistant to 'first-line' chemotherapyfrom Science DailyWed, 13 Jan 2010, 12:21:25 EST
- Green tea could modify the effect of cigarette smoking on lung cancer riskfrom Science CentricWed, 13 Jan 2010, 10:21:16 EST
- MicroRNA profiling identifies chemoresistance in small cell lung cancerfrom Science CentricWed, 13 Jan 2010, 9:49:10 EST
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
No popular news yet
No popular news yet
- Stem cell transplant restores memory, learning in mice
- Superstorm Sandy shook the US
- 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
- Calculating tsunami risk for the US East Coast
- Researchers discover mushrooms can provide as much vitamin D as supplements